Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Pyrazinamide — on the antituberculosis drug frontline

Nature Medicine volume 2, pages 635–636 (1996)Cite this article

Finding the gene responsible for activating pyrazinamide opens the door to rapid testing for drug resistance (pages 662–667).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Mitchison, D.A. The Garrod Lecture. Understanding the chemotherapy of tuberculosis — current problems. J. Antimicrob. Chemo. 29, 477–493 (1992).

    Article  CAS  Google Scholar 

  2. McDermott, W. & Tompsett, R. Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am. Rev. Tuberc. 70, 748–754 (1954).

    CAS  PubMed  Google Scholar 

  3. McCune, R.M., Tompsett, R. & McDermott, W. The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. J. Exp. Med. 104, 763–803 (1956).

    Article  CAS  Google Scholar 

  4. Mitchison, D.A. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 66, 219–225 (1985).

    Article  CAS  Google Scholar 

  5. Konno, K., Feldmann, F.M. & McDermott, W. Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am. Rev. Respir. Dis. 95, 461–469 (1967).

    CAS  PubMed  Google Scholar 

  6. Cynamon, M.H. et al. Pyrazinoic acid esters with broad spectrum in vitro anti-mycobacterial activity. J. Med. Chem. 38, 3902–3907 (1995).

    Article  CAS  Google Scholar 

  7. Crowle, A.J., Dahl, R., Ross, E. & May, M.H. Evidence that vesicles containing living, virulent Mycobacterium tuberculosis or Mycobacterium avium in cultured human macrophages are not acidic. Infect. Immun. 59, 1823–1831 (1991).

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Scorpio, A. & Zhang, Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to antituberculous drug pyrazinamide in tubercle bacillus. Nature Med. 2, 662–667 (1996).

    Article  CAS  Google Scholar 

  9. Brander, E. A simple way of detecting pyrazinamide resistance. Tubercle, 53, 128–131 (1972).

    Article  CAS  Google Scholar 

  10. Cole, S.T. Mycobacterium tuberculosis: Drug resistance mechanisms. Trends Microbiol. 2, 411–415 (1994).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Microbiology, St George's Hospital Medical School, Cranmer Terrace, London, SW17 ORE, UK

    Denis A. Mitchison

Authors
  1. Denis A. Mitchison
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mitchison, D. Pyrazinamide — on the antituberculosis drug frontline. Nat Med 2, 635–636 (1996). https://doi.org/10.1038/nm0696-635

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0696-635

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing